IM Cannabis Out with Q2 Figures
IM Cannabis Corp. (NASDAQ: IMCC) shares gained Tuesday. The firm, international medical cannabis company, announced its financial results today for the second quarter ended June 30, 2025. All amounts are compared to the quarter ended June 30, 2024, unless otherwise stated.
The company reported a 14% Revenue decrease vs. Q2 2024 of $12.7M vs. $14.8M
EBITDA profit was $100,000 in Q2 2025 vs. EBITDA loss of $2.3M in Q2 2024.
Net loss in Q2 2025 was $0.2 million, compared to net loss of $3.5 million in Q2 2024.
Said Chief Financial Officer Uri Birenberg, “In Q2, we achieved a 306% increase in gross profit to $3.4 million compared to $0.8 million last year, alongside a 105% improvement in Non-IFRS Adjusted EBITDA to a profit of $0.1 million from a $2.3 million loss.
These results reflect disciplined cost management, operational efficiency, and margin expansion, even amid a 14% revenue decline driven by the ongoing war in Israel and supply chain delays. We remain focused on strengthening our balance sheet and positioning the company for sustainable, profitable growth as market conditions normalize.”
IMC is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets.
IMCC’s stock price advanced seven cents, or 2.5%, Tuesday morning to $2.92.
